Horizon Discovery

About:

Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.

Website: http://www.horizondiscovery.com

Twitter/X: horizongenomics

Top Investors: Molten Ventures, Parkwalk Advisors, Jonathan Milner, ValueAct Capital, MVM Life Science Partners

Description:

Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.

Total Funding Amount:

$38.5M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2007-06-01

Contact Email:

info(AT)horizondiscovery.com

Founders:

Alberto Bardelli, Chris Torrance, Darrin Disley

Number of Employees:

101-250

Last Funding Date:

2018-09-07

IPO Status:

Public

Industries:

© 2025 bioDAO.ai